3104109-31-8
Chemical Structure
JAK3-IN-20
- CAS No.: 3104109-31-8
- Formula:C24H31ClN8O2
- Molecular Weight:499.01
InChIKey: UTFURAIIFQCVBQ-UHFFFAOYSA-N
SMILES: C=CC(N1CCCC(C1)COC2=NC(NC3=CN(N=C3)C4CCN(CC4)C)=NC5=C2C(Cl)=CN5)=O
Biological Activity: JAK3-IN-20 is a selective and orally active JAK3 inhibitor with an IC50 of 0.7473 nM. JAK3-IN-20 forms a covalent bond with JAK3 Cys909, outcompetes ATP for catalytic site binding, and blocks JAK-STAT pathway activation. JAK3-IN-20 inhibits migration, proliferation, and tumor growth of Bortezomib (HY-10227)-resistant cancer cells. JAK3-IN-20 induces dose-dependent apoptosis. JAK3-IN-20 can be used for the research of Bortezomib-resistant multiple myeloma[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JAK3-IN-20 | JAK3-IN-20 is a selective and orally active JAK3 inhibitor with an IC50 of 0.7473 nM. JAK3-IN-20 forms a covalent bond with JAK3 Cys909, outcompetes ATP for catalytic site binding, and blocks JAK-STAT pathway activation. JAK3-IN-20 inhibits migration, proliferation, and tumor growth of Bortezomib (HY-10227)-resistant cancer cells. JAK3-IN-20 induces dose-dependent apoptosis. JAK3-IN-20 can be used for the research of Bortezomib-resistant multiple myeloma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
